WINDOCRE

Treatment tested

• Ocrelizumab

  B-lymphocyte antigen CD20 binding agent

Other measures (14)

Inclusion: - Patient 18 years or older - Coming for a 4th semester cycle of ocrelizumab (at least) - Requires follow-up cerebral-medullary MRI as part of care - Who had relapsing remitting or secondarily progressive MS at the time of initiation of anti-CD20 (ocrelizumab or rituximab) therapy : relapse or radiological activity in the year priori to initiation of high-efficacy treatment - No relapse for at least 18 months - EDSS between 0 and 6 inclusive - Having received information about the study and having signed a consent to participate in the study - Knowledge of the French language - Affiliated or beneficiary to a social security scheme Exclusion: - Clinical forms of primary progressive multiple sclerosis (PP) - Pregnant woman - Patients already receiving routine spacing ≥ 9 months of ocrelizumab doses - Contra-indication to continued treatment with ocrelizumab (hypersensitivity reaction, ongoing active infection, development of a malgnant disease since the previous inhection, development of a severe immune deficiency) - Planning a pregnancy within 3 years - Contra-indication to MRI - Contra-indication to the injection of contrast products - Subjects with severe or uncontrolled symptoms of renal, hepatic, haematological, gastrointestinal, pulmonary, psychiatric or cardiac disease or any uncontrolled intercurrent disease - Patient under legal protection measure - Patients of childbearing potential who do not wish to use effective contraception during their participation and at least 4 months after the last dose (oral commitment of the patient recorded in the medical file by the investigator)

To compare the efficacy of a treatment plan with annual administrations of ocrelizumab versus a conventional treatment plan with semi-annual administrations, on the absence of radiological disease activity at 2 years, in patients with active MS treated for at least 2 years with ocrelizumab